Your Guide to Finding the Best Psychiatrist in Los Angeles

Complex post-traumatic stress disorder (CPTSD) is a unique form of traumatic stress disorder. It develops as a result of prolonged exposure to traumatic events, especially in situations where escape or avoidance is not possible. Unlike classic PTSD, complex PTSD is characterized not only by a reaction to a single traumatic event. Profound changes in emotional regulation, self-perception, and relationships with others also characterize it.

Structured recovery stages play a key role in healing from this problem. They provide a solid foundation for gradual and steady progress. This allows people to move at their own pace, respecting their path to recovery. It is important to realize that healing is possible. Remember, many people successfully overcome the effects of trauma and return to a full and fulfilling life.

What are the symptoms of complex PTSD?

Complex PTSD manifests itself through many interrelated symptoms. Each of them can significantly affect a person's daily life. When the problem is pronounced, not all symptoms necessarily manifest. But some symptoms include:

• Flashbacks formation and intrusive memories. They can occur suddenly and can be extremely realistic. A person may not only visually relive the traumatic events but may also experience physical sensations, smells, and sounds associated with the trauma. These memories often invade the mind without warning, disrupting daily activities.
• Avoidance of reminders of the trauma. This problem with CPTSD manifests itself in a desire to avoid places, people, or situations that may trigger painful memories. It can lead to a significant narrowing of living space and social isolation.
• Difficulty regulating emotions. These conditions manifest themselves in sudden mood swings, outbursts of anger, or deep sadness. The person may have difficulty identifying their feelings or feel emotionally numb.
• Chronic feelings of guilt, shame, or worthlessness. These symptoms often become part of the self-image. People may constantly criticize themselves, feeling "spoiled" or unworthy of happiness and love.
• Dissociation and feeling disconnected from reality. These problems can manifest as a feeling of unreality about what is happening, disconnected from one's own body or emotions. Some describe it as a feeling of "autopilot" or watching your life from the outside.
• Difficulty trusting and maintaining relationships. In complex PTSD, these symptoms are often associated with a deep distrust of people and fear of betrayal. It can manifest in difficulty establishing intimacy, maintaining friendships, or creating romantic connections.

The Three Key Stages of Complex PTSD Recovery

Healing from CPTSD is a structured process that requires a sequential approach. The recovery stages allow for a gradual progression toward recovery, taking into account the individual characteristics of each person. Although the path is not always linear, each stage sets the stage for the next step toward healing.

Establishing Safety and Stabilization

The first and fundamental recovery stages begin with creating a safe physical and emotional environment. This is the cornerstone of the healing process, without which no further progress is possible.

Creating physical safety includes:

• Providing safe housing
• Establishing a stable daily routine
• Meeting basic needs for food, sleep, and physical activity
• Ensuring financial stability

Developing emotional safety involves:

• Mastering stress management techniques (deep breathing, meditation)
• Practicing grounding exercises
• Working with a professional therapist
• Creating a support system of trusted people

At Amae Health, specialists help develop an individualized stabilization plan tailored to each person's unique needs and circumstances. Regular sessions with a therapist create a safe space to explore emotions and develop coping skills.

Processing Traumatic Memories

Once a sufficient level of stability has been achieved, the second stage of overcoming PTSD begins - working with traumatic memories. This stage requires special care and professional support.

Methods of trauma-focused therapy:

• EMDR (Eye Movement Desensitization and Reprocessing):
  
  • Helps to process traumatic memories
  • Reduces the emotional intensity of the memories
  • Promotes integration of traumatic experiences
• Cognitive Behavioral Therapy (CBT):
  
  • Helps identify and change unhealthy thinking patterns
  • Develops anxiety management skills
  • Teaches more adaptive ways of responding
• Somatic Therapy:
  
  • Works with the bodily manifestations of trauma
  • Helps to reconnect with the body
  • Develops the ability to feel safe on a physical level

It is important to realize that processing traumatic memories is not simply retelling traumatic events. It is a controlled process designed to integrate the experience without re-traumatizing it. Grieving and mourning losses are a natural part of this process.

Reconnecting with Daily Life

The third recovery stage focuses on reintegration into everyday life and building a new future. This is when a person re-establish social ties and finds new meaning in life.

Key aspects of reintegration:

• Rebuilding relationships:
  
  • The gradual building of trust
  • Developing communication skills
  • Establishing healthy boundaries
• Developing interests and hobbies:
  
  • Exploring new activities
  • Returning to previous hobbies
  • Developing creative self-expression
• Setting and achieving goals:
  
  • Starting with small, achievable goals
  • Gradually expanding horizons
  • Celebrating each success

It's important to remember that progress is rarely linear. Temporary setbacks are a normal part of the recovery process, not a sign of failure.

Therapeutic Approaches in CPTSD Recovery

Psychotherapy Modalities

Amae Health utilizes a variety of therapeutic approaches tailored to each client's individual needs:

• Dialectical Behavioral Therapy (DBT):
  
  • Develops emotional regulation skills
  • Teaches acceptance and change
  • Helps you cope with crises
• Intra-Family Systems Therapy (IFS):
  
  • Works with different parts of the personality
  • Helps restore inner harmony
  • Promotes self-understanding and acceptance
• Somatic Therapy:
  
  • Restores connection with the body
  • Helps to recognize and regulate bodily sensations
  • Develops resource states

Medication Management

Medication therapy can be a useful adjunct to psychotherapy, although it is not in itself a treatment for CPTSD.

The main groups of medications are:

• Antidepressants (SSRIs, SNRIs) - help manage symptoms of depression and anxiety
• Mood stabilizers - maintain emotional stability
• Sleep medications - help with sleep disorders

It is important to remember that any medication should only be taken under the supervision of a qualified professional. While medications may alleviate certain symptoms, lasting improvement in CPTSD often comes through trauma-focused therapy. Intensive trauma-based treatments have been shown to significantly reduce CPTSD symptoms, with over 85% of patients in one study no longer meeting diagnostic criteria after just eight days of structured therapy.

Holistic & Self-Help Strategies for CPTSD Recovery

Lifestyle Adjustments for Long-Term Healing

Physical Well-being:

• Regular exercise helps reduce stress and improve mood
• A healthy diet supports energy balance
• Quality sleep helps restore the nervous system

Emotional Well-being:

• Practicing mindfulness helps you stay in the present moment
• Meditation reduces anxiety and improves concentration
• Breathing exercises help regulate the emotional state

Building a Personal Support Network

Importance of social support:

• Support groups provide an opportunity to socialize with people with similar experiences from complex PTSD
• Online forums can be a source of information and support
• Healthy boundaries protect against re-traumatization

Building supportive relationships:

• Gradual development of trust
• Open communication about your needs
• Respect for personal boundaries

Your Recovery Journey: What Comes Next?

Recovery from CPTSD is a journey that takes time, patience and support. Every step forward, even the smallest, is a meaningful accomplishment. It is important to remember that you are not alone on this journey.

‍The leadership team at Amae Health brings together deep clinical expertise, personal commitment, and a mission to guide you through every step of recovery. Our professionals take a comprehensive approach, combining a variety of therapies and support methods customized to your individual needs.

Recovery is possible. Every day, people overcome the effects of trauma and return to a full life. Your ability to seek help is already a manifestation of your inner strength and commitment to healing.

Remember what is important in the recovery process:

• Move at your own pace
• Celebrate every accomplishment, even small ones
• Be patient and kind to yourself
• Don't hesitate to ask for help when you need it

Recovery stages from CPTSD may seem difficult, but each step brings you closer to healing. With the right support and tools, you can build a new, more fulfilling life after trauma.

‍

Spravato success rate figures are easy to find and hard to compare. In the trial that supported its FDA approval, 69.3% of people who finished 4 weeks of Spravato with a new antidepressant had responded, and 52.5% were in remission. A study of routine care in Italy found 64.2% response and 40.6% remission at 3 months. The numbers answer slightly different questions, but they agree on the essentials: Spravato helps many people with treatment-resistant depression, response is more common than remission, and no single percentage tells the whole story.

Spravato also leaves a real share of people without enough relief.

Spravato is the brand name for esketamine, a nasal spray FDA-approved for treatment-resistant depression: depression that hasn't responded adequately to at least two antidepressants, each given at a proper dose for long enough.

What "Success" Means: Response vs. Remission

Nearly every Spravato statistic comes from one yardstick, the Montgomery-Åsberg Depression Rating Scale (MADRS). It's a 10-item interview a clinician scores from 0 to 60, where higher means more severe, and people entering Spravato's main approval trial averaged about 37. Two thresholds turn that score into a success rate:

• Response means the MADRS score has fallen by at least half from where it started.
• Remission means the score has dropped to 12 or lower, the cutoff the Spravato trials used.

The distance between the two is wide. Someone who starts at 38 and falls to 19 counts as a responder and may still have symptoms that get in the way of work, sleep, or relationships. Remission is the fuller recovery and the harder bar, so every remission figure below sits under its response figure.

Spravato's Success Rate in the Trial Behind Its Approval

The short-term trial that supported FDA approval was TRANSFORM-2, published in The American Journal of Psychiatry in 2019. Researchers at 39 outpatient centers enrolled adults with moderate to severe depression who hadn't responded to at least two antidepressants in their current episode. Everyone switched to a new oral antidepressant. One group also received Spravato, 56 or 84 mg twice a week, and the other a placebo spray. Of 227 people randomized, 197 finished the 4-week double-blind phase, and MADRS scores in the Spravato group fell 4 points more, on average.

The European Medicines Agency's review of the trial data translates that into response and remission:

Look first at the comparison group: more than half of the people who started a new antidepressant with a placebo spray also responded. The trial's finding is the gap. Among people who completed 4 weeks, adding Spravato meant about 17 more responders and 21 more remitters in every 100.

The counting method matters too, and it explains much of the inconsistency online. Figures near 69% count only people who finished. Figures near 63% for response, or 48% for remission, carry forward the last score of everyone who stopped early.

Real-World Success Rates

Trials select their patients carefully and follow them for weeks. Routine care is messier, which is what makes REAL-ESK useful. That 2022 study, published in the Journal of Affective Disorders, reviewed the medical records of 116 people with treatment-resistant depression treated with Spravato at several Italian mental health services, with assessments at 1 and 3 months.

By 3 months, 64.2% had responded and 40.6% were in remission, and both rates had climbed sharply between the first month and the third. The authors called that later response one of the study's novel findings. They also found no difference in effectiveness between people with other psychiatric conditions and people without them.

Lining those numbers up against TRANSFORM-2 doesn't work cleanly. REAL-ESK had no placebo or comparison group, everyone knew they were receiving Spravato, ratings weren't checked for consistency across centers, and 3 months is a different finish line from 4 weeks. It's encouraging evidence from everyday practice, not a controlled measure of effect.

Who Spravato Is Approved and Studied For

Spravato has two FDA-approved uses, built on separate trials, according to its prescribing information:

• Treatment-resistant depression in adults, on its own or with an oral antidepressant. The original 2019 approval required an oral antidepressant alongside it; standalone use was added in January 2025.
• Depression with acute suicidal thoughts or behavior, in adults with major depressive disorder, given alongside an oral antidepressant to treat the depressive symptoms.

The second use came from trials of a different group: adults with moderate to severe depression and active suicidal thoughts with intent, all of whom began with an inpatient psychiatric stay and standard care, and 63% of whom had attempted suicide before. Those results shouldn't be mixed with the treatment-resistant depression results.

The label is explicit about one boundary. Spravato hasn't been shown to prevent suicide or to reduce suicidal thoughts or behavior, and it doesn't replace hospitalization when that's needed, even if someone feels better after the first dose. It isn't approved for children. If suicidal thoughts are part of what you're living with right now, care for suicidal thoughts comes first, and 988 answers calls and texts at any hour.

How Fast Results Typically Appear

Spravato's reputation for speed comes from the first day. In TRANSFORM-2, most of the difference from placebo was already visible at 24 hours, the label reports; both groups kept improving through day 28, and the gap held steady rather than widening. The monotherapy trial behind the 2025 approval showed an effect at about 24 hours that lasted through day 28. In the suicidal-thoughts trials, the difference appeared as early as 4 hours.

Early movement isn't the same as response. In TRANSFORM-2, only 7.9% of people on Spravato had a response that began by day 2 and held through day 28, compared with 4.6% on placebo spray, a difference that wasn't statistically significant in the EMA review. The label calls for judging benefit at the end of the 4-week induction phase, after which sessions drop from twice a week to weekly.

And as REAL-ESK suggests, for some people even 4 weeks is early.

What Affects Individual Success

Research points to a handful of factors linked to outcomes, none of them a forecast for any one person:

• Time on treatment. Benefit is formally assessed after the 4-week induction phase, and in REAL-ESK, many responses and remissions arrived between the first and third month.
• Continuing after a good response. In a maintenance study described in the label, people in stable remission who kept taking Spravato went significantly longer before relapsing than people switched to a placebo spray, and the same held for people in stable response.
• Age. The evidence is weaker in older adults. In a separate short-term trial of adults 65 and older, response at day 28 was 27.0% with Spravato versus 13.3% with placebo spray, and the trial's main measure narrowly missed statistical significance, per the EMA review.
• Other psychiatric conditions. REAL-ESK found people with additional psychiatric diagnoses did as well as people without them.
• With or without an oral antidepressant. Spravato has shown benefit both ways, but no trial in the label compared the two head to head.

Limits and Risks

The same data show where Spravato falls short.

• Many people don't reach remission. Nearly half of the people who completed TRANSFORM-2 on Spravato weren't in remission at day 28, and in REAL-ESK, about six in 10 weren't in remission at 3 months.
• Not every trial was positive. Of the three short-term trials submitted for approval, only TRANSFORM-2 met its main goal. A fixed-dose trial in adults and the trial in older adults both fell short of statistical significance, according to the EMA review.
• It carries a boxed warning for sedation, dissociation, breathing problems (respiratory depression), and misuse or abuse, plus the risk of suicidal thoughts and behaviors that antidepressants carry for children and young adults. Sedation showed up in 48% to 61% of trial participants on Spravato, and dissociation, a sense of detachment that can warp time, space, or surroundings, in 61% to 84%.

Those risks shape how Spravato is given. It's only available through a restricted program called the Spravato REMS. You use the spray yourself under supervision in a certified healthcare setting, your blood pressure is checked before and after, and you're monitored for at least 2 hours before you're cleared to leave. Driving is off-limits until the next day, after a night of restful sleep. People with certain blood vessel problems, including an aneurysm, an abnormal connection between arteries and veins, or past bleeding in the brain, can't take it at all.

Talking to a Psychiatrist About Your Options

A Spravato success rate is a group statistic. It shows that Spravato helps a substantial share of people with treatment-resistant depression and that remission is harder to reach than response. It can't tell you what will happen for you. That depends on your diagnosis, what you've tried and for how long, your medical history, and the rest of your care.

We don't offer Spravato at Amae. Major depressive disorder is among the conditions our clinics specialize in, and when it hasn't eased with medication, our psychiatrists treat it within our integrated care model, which puts psychiatry, medication management, therapy, and primary care on one team. TMS therapy runs at three of our clinics: Los Angeles, Los Altos, and San Mateo. Our comparison of TMS, ketamine, and Spravato and our look at TMS success rates lay out how those options differ. To go over your history with someone who can see all of it, schedule an evaluation with an Amae psychiatrist. Anyone in immediate danger should call 911.

Frequently Asked Questions

What is Spravato's success rate in clinical trials?

In TRANSFORM-2, the short-term trial behind FDA approval, 69.3% of people who completed 4 weeks of Spravato plus a new antidepressant responded and 52.5% reached remission, versus 52.0% and 31.0% with a placebo spray plus a new antidepressant. Counting people who left early, remission was 48.2% versus 30.3%.

Does Spravato work better in real-world use than in trials?

The figures look similar, but they can't be compared directly. REAL-ESK, a study of 116 people treated in routine care in Italy, found 64.2% response and 40.6% remission at 3 months, with no placebo group and a longer follow-up than the 4-week trials.

How fast does Spravato start working?

Average scores often pull ahead of placebo within 24 hours, and in trials of people with suicidal thoughts, within 4 hours. A lasting response that early is uncommon, so benefit is judged after the 4-week induction phase, and some people improve later still.

Does Spravato work for everyone?

No. In TRANSFORM-2, nearly a third of people who completed treatment didn't respond, and nearly half didn't reach remission. Two other short-term trials, including one in adults 65 and older, didn't reach statistical significance on their main measure.

What happens if Spravato doesn't work for me?

A psychiatrist looks at the whole picture again: the diagnosis, whether treatment ran long enough, other medications, and other conditions. Next steps might include a different medication strategy, adding or changing therapy, or another treatment for treatment-resistant depression, such as TMS or ECT.

Is Spravato's success rate different for suicidal depression versus treatment-resistant depression?

Yes, and the two shouldn't be blended. The suicidal-thoughts trials measured average score changes 24 hours after the first dose in hospitalized adults receiving standard care. Spravato lowered depression scores more than placebo, but it didn't improve a rating of suicidality more than placebo, and it hasn't been shown to reduce suicidal thoughts.

Citations

1. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. The American Journal of Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/ (Tier 1)
2. European Medicines Agency. Spravato: EPAR public assessment report (EMA/614876/2019). 2019. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf (Tier 2, regulatory review)
3. Martinotti G, Vita A, Fagiolini A, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders. 2022;319:646-654. https://pubmed.ncbi.nlm.nih.gov/36167246/ (Tier 1)
4. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised April 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf (Tier 2)
5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

From the outside, you look fine. You show up, you apologize first, you keep your voice level. Inside, a small comment from a friend can set off hours of shame, a spiral of "they're going to leave," and a quiet decision to pull away before anyone can hurt you. That pattern has a name people search for: quiet BPD. It describes borderline personality disorder (BPD) turned inward, where the intense emotions are real but almost nobody sees them.

Quiet BPD isn't a separate diagnosis. It's a way of describing how BPD can look when anger, fear, and despair are directed at yourself instead of at other people. And because it's so easy to miss, people often live with it for years before anyone names it.

Is quiet BPD a real diagnosis?

Not formally. The DSM-5 describes one borderline personality disorder, with no official subtypes. "Quiet BPD," "silent BPD," "internalized BPD," and "hidden BPD" are informal terms that patients and clinicians use for the same inward-facing pattern.

The idea has roots in research, though. Psychologist Theodore Millon described four subtypes of BPD, including a "discouraged" type and a "petulant" type. The discouraged type, marked by avoidant and dependent traits, unexpressed anger, guilt, and shame, is the closest match to what people now call quiet BPD. (We've written separately about the outward-facing petulant type of BPD.)

Newer data points the same way. A 2023 study of 109 patients with BPD in a psychiatric day clinic, published in Personality Disorders: Theory, Research, and Treatment, sorted patients into three groups by symptom pattern. Thirty-five fit an "internalizing" profile, and that group had more co-occurring mood disorders than the others.

So the label is informal. The pattern is not.

Quiet BPD symptoms and signs

The core symptoms of quiet BPD are the same ones the NIMH lists for borderline personality disorder. What changes is the direction they travel.

• Fear of abandonment shows up as hypervigilance and pre-emptive withdrawal. You don't beg someone to stay. You leave first, or go silent, so the rejection can't land.
• Intense, shifting moods happen behind a calm face. An episode can last a few hours to a few days, and the people around you may never know it happened.
• Anger gets swallowed and turned into self-criticism. Instead of an outburst, there's a long internal prosecution of everything you did wrong.
• An unstable sense of self feels like not knowing who you are without someone else's approval, and shape-shifting to fit whoever you're with.
• Chronic emptiness can look like flatness or "I'm just tired" to everyone else.
• Dissociation, feeling cut off from yourself or your surroundings, often under stress.
• Rejection sensitivity: replaying a conversation for days, reading a short text as proof someone is done with you.
• Self-harm or suicidal thoughts, kept hidden.

People with this presentation are often described as perfectionists, people-pleasers, or "the easy one" in the family. That's part of why the condition goes unrecognized.

Quiet BPD vs. "classic" BPD

The difference isn't severity. It's visibility.

In the presentation most people picture, distress spills outward: arguments, accusations, impulsive spending or drinking, visible crises in relationships. In quiet BPD, the same emotional storm happens internally. The person who might shout "you never cared about me" instead thinks "of course they don't care, I'm too much," and quietly stops replying to messages.

Both reflect the same underlying difficulty regulating emotions. Both cause real suffering. One is just far easier to overlook.

Why quiet BPD gets missed

Quiet BPD often arrives in a clinic labeled as something else, usually depression or anxiety. The internal pattern of shame, emptiness, and withdrawal overlaps heavily with both, and BPD frequently co-occurs with them: the NIMH notes that people with BPD may also experience depression, anxiety disorders, PTSD, eating disorders, and substance use disorders. If you're treated for depression alone and keep cycling back, the underlying pattern may not have been named. (For more on that overlap, see how anxiety and depression overlap.)

There's a second reason. People with quiet BPD are skilled at appearing okay, including in a therapist's office. They minimize. They worry about being a burden. A clinician who only sees the composed surface can miss what's underneath.

What causes quiet BPD?

No single cause explains BPD, quiet or otherwise. Genes and environment both contribute.

On the genetic side, a 2021 study of more than 1.8 million people in Swedish national registries estimated the heritability of diagnosed BPD at 46%. Risk was highest among identical twins and fell as relatives became more distant. The remaining variance came from environmental factors unique to each person.

On the environmental side, clinicians often hear about childhoods where feelings were dismissed, punished, or simply never acknowledged. Some people learned early that expressing anger or need made things worse, so they stopped. That's one plausible route from a sensitive temperament to an inward-facing pattern, though research hasn't yet separated what makes one person's BPD quiet and another's outward.

Self-harm and safety

Quiet doesn't mean low-risk. The NIMH notes that people with BPD are more likely to engage in self-harm, and the inward-facing pattern makes it easier to hide. Families sometimes learn about self-harm or suicidal thoughts only after a crisis.

If you or someone you love is having thoughts of suicide, call or text the 988 Suicide & Crisis Lifeline at 988. In an emergency, call 911.

Treatment for quiet BPD

BPD is treatable, and the evidence is strongest for specialized psychotherapy. A 2020 Cochrane review pooled 75 randomized trials with 4,507 participants. Across 22 trials comparing psychotherapy with usual care, therapy reduced BPD symptom severity. The two most-studied approaches were:

• Dialectical behavior therapy (DBT), which was developed specifically for BPD and teaches skills for intense emotions, distress tolerance, and relationships.
• Mentalization-based treatment (MBT), which builds the ability to understand your own and other people's mental states, especially under stress.

For quiet BPD, part of the work is simply making the inner experience visible: learning to notice and name anger, shame, and fear before they turn into silent withdrawal.

Medication plays a supporting role. According to the NIMH, the benefits of medication for BPD are unclear and it isn't a first-line treatment. Clinicians may use it alongside therapy for specific symptoms or co-occurring conditions such as depression.

Can quiet BPD get better?

Yes. There's no long-term research on quiet BPD specifically, but the data on BPD overall is more hopeful than most people expect. In a 10-year study of 290 adults with BPD first assessed during a psychiatric hospital stay, published in the American Journal of Psychiatry in 2010, 93% reached a symptom remission lasting at least two years. Full recovery, meaning remission plus good work and social functioning, was harder: about half got there. That gap is the case for treatment that goes beyond symptoms to rebuild relationships, work, and daily life.

How we treat BPD at Amae Health

Borderline Personality Disorder is one of the conditions our clinics specialize in. Our care teams bring psychiatrists, therapists, primary care physicians, peer mentors, and care coordinators under one roof, working from one treatment plan. For someone with quiet BPD, that matters: the more people who know your history, the harder it is for a composed surface to hide what's going on. Read more about how we approach care.

Frequently asked questions

Is quiet BPD real?

Yes, as a pattern. "Quiet BPD" isn't an official DSM-5 diagnosis, but it describes a recognized way borderline personality disorder can present, close to the "discouraged" subtype Theodore Millon described and the "internalizing" group seen in newer research.

Is there a test for quiet BPD?

There's no validated test for quiet BPD specifically. Online quizzes can prompt reflection, but a BPD diagnosis comes from a clinical evaluation by a mental health professional who looks at your history, patterns over time, and co-occurring conditions.

How is quiet BPD different from depression?

They overlap and often occur together. Depression centers on low mood and loss of interest. Quiet BPD adds intense fear of abandonment, an unstable sense of self, rapid shifts in mood, and relationship patterns driven by rejection sensitivity.

How can I help someone with quiet BPD?

Notice withdrawal instead of reading it as disinterest, and ask directly how they're doing. Avoid pressing for an explanation in the moment. Our guide on how to help someone with mental health issues covers more. If they mention self-harm or suicide, take it seriously and contact 988.

Key takeaways

• Quiet BPD is an informal name for borderline personality disorder expressed inward: hidden anger, shame, withdrawal, and self-blame.
• It's not a separate DSM-5 diagnosis, but research has identified a similar "internalizing" pattern.
• It's often mistaken for depression or anxiety, and self-harm can stay hidden.
• Specialized psychotherapy such as DBT and MBT has the strongest evidence, and long-term remission is common.

If you recognize yourself here, or you're worried about someone who seems fine but isn't, you can request an intake appointment. Our team will explain how an evaluation works and what to expect from your first visit.